These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 2895008)

  • 1. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
    Andersen PH
    Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
    Andersen PH; Nielsen EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo.
    Andersen PH; Grønvald FC
    Life Sci; 1986 Apr; 38(16):1507-14. PubMed ID: 2871467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
    Tarazi FI; Florijn WJ; Creese I
    Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy.
    Andersen PH; Jansen JA
    Eur J Pharmacol; 1990 Jun; 188(6):335-47. PubMed ID: 1973652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.
    Hall H; Farde L; Sedvall G
    J Neural Transm; 1988; 73(1):7-21. PubMed ID: 2969950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ; Tarazi FI; Creese I
    J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.
    Seeman P; Niznik HB; Guan HC; Booth G; Ulpian C
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10156-60. PubMed ID: 2574862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P; Lesourd M; Comoy E
    Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
    Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The inhibition of dopamine D1 and D2 receptors in human putamen by antipsychotic drugs].
    Kobayashi T; Shimizu H; Toru M
    Yakubutsu Seishin Kodo; 1990 Jun; 10(2):331-4. PubMed ID: 1979198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
    Protais P; Chagraoui A; Arbaoui J; Mocaër E
    Eur J Pharmacol; 1994 Dec; 271(1):167-77. PubMed ID: 7698199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H; Sällemark M
    Pharmacol Toxicol; 1987 May; 60(5):359-63. PubMed ID: 2886988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
    Peacock L; Lublin H; Gerlach J
    Eur J Pharmacol; 1990 Sep; 186(1):49-59. PubMed ID: 1980891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.